From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

The appointment of seven Supreme Court judges under Chief Justice of Pakistan (CJP) Yahya Afridi has sparked concerns that ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...

The Federal Public Service Commission (FPSC) has officially confirmed that the Central Superior Services (CSS) 2025 examination will proceed as planned, beginning tomorrow (Saturday, 5, 2025).

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

This important study focused on characterizing clonally derived MSC populations from the synovium of normal and osteoarthritis (OA) patients, demonstrating their potential to regenerate cartilage in ...

It was a great week for the West Genesee boys ice hockey team beyond the fact that it completed its own unbeaten regular season. Before it even took the ice the Wildcats found itself back in first ...